"The Economic Report" Show to Feature Theranostics Health
Coral Springs, FL, August 30, 2009 --(PR.com)-- The producers of The Economic Report are pleased to announce that Theranostics Health will be featured in an upcoming episode as part of the show’s Medical Minutes series on Innovative Drug Discovery Technologies.
A biomarker is an indicator of a biological state that can be used to objectively measure a normal biological process, disease, or even to predict or evaluate response to therapies. In the past, biomarkers were generally meant to be single whole molecules, such as prostate-specific antigen, measured in a body fluid sample. Today, biomarker science is brimming with new technologies, new candidates and brand new applications that are supplying urgent human health needs in the near-term. Anything from tissue, sweat, hair, and even exhaled breath are used to obtain biomarkers which now consist of all classes of molecules, including RNA, miRNA, DNA, proteins, lipids and sugars. New dimensions of functional insights are emerging from incorporating the ‘processing history’ of these biomarker molecules, including for example, measuring the phosphorylation states of proteins. Molecular insights from this biomarker renaissance are the driving force behind the movement towards personalized medicine.
Maryland-based Theranostics Health, an emerging leader in personalized medicine, is shaping and creating a new healthcare and disease management system in which the best tailored treatments are provided to individual patients. Their unique technologies encapsulate the entire protein biomarker analysis workflow including Laser Capture Microdissection (LCM) combined with Reverse Phase Protein Microarray (RPMA), which measure the activity of a large number of biomarkers to profile protein activities and the cellular circuitry of signaling pathways. This technology allows pharmaceutical developers to accurately assess the effectiveness of their proprietary drugs and physicians to tailor optimized personalized therapies to their patients. Currently, most molecularly-targeted drugs act on protein targets and because Theranostic Health’s technology directly measures the state of drug targets, researchers utilizing their technology are provided with significant advantages.
“Theranostics Health is at the forefront of bringing personalized medicine to the marketplace,” said Dr. Danong Chen, President and CEO of Theranostics Health. “Our technology can profile disease at a molecular level and can precisely test the activation of drug targets in diseased specimens. Our products will provide accurate information for physicians to practice evidence-based medicine. The emergence of companion and molecular diagnostics not only has led and will continue to lead the growth of the diagnostics industry, but also transform the practice of medicine and the entire healthcare industry.”
For more information, please visit www.theranosticshealth.com.
###
A biomarker is an indicator of a biological state that can be used to objectively measure a normal biological process, disease, or even to predict or evaluate response to therapies. In the past, biomarkers were generally meant to be single whole molecules, such as prostate-specific antigen, measured in a body fluid sample. Today, biomarker science is brimming with new technologies, new candidates and brand new applications that are supplying urgent human health needs in the near-term. Anything from tissue, sweat, hair, and even exhaled breath are used to obtain biomarkers which now consist of all classes of molecules, including RNA, miRNA, DNA, proteins, lipids and sugars. New dimensions of functional insights are emerging from incorporating the ‘processing history’ of these biomarker molecules, including for example, measuring the phosphorylation states of proteins. Molecular insights from this biomarker renaissance are the driving force behind the movement towards personalized medicine.
Maryland-based Theranostics Health, an emerging leader in personalized medicine, is shaping and creating a new healthcare and disease management system in which the best tailored treatments are provided to individual patients. Their unique technologies encapsulate the entire protein biomarker analysis workflow including Laser Capture Microdissection (LCM) combined with Reverse Phase Protein Microarray (RPMA), which measure the activity of a large number of biomarkers to profile protein activities and the cellular circuitry of signaling pathways. This technology allows pharmaceutical developers to accurately assess the effectiveness of their proprietary drugs and physicians to tailor optimized personalized therapies to their patients. Currently, most molecularly-targeted drugs act on protein targets and because Theranostic Health’s technology directly measures the state of drug targets, researchers utilizing their technology are provided with significant advantages.
“Theranostics Health is at the forefront of bringing personalized medicine to the marketplace,” said Dr. Danong Chen, President and CEO of Theranostics Health. “Our technology can profile disease at a molecular level and can precisely test the activation of drug targets in diseased specimens. Our products will provide accurate information for physicians to practice evidence-based medicine. The emergence of companion and molecular diagnostics not only has led and will continue to lead the growth of the diagnostics industry, but also transform the practice of medicine and the entire healthcare industry.”
For more information, please visit www.theranosticshealth.com.
###
Contact
Theranostics Health
Mary DeMarco
301-251-4443
www.theranosticshealth.com
Mary DeMarco
301-251-4443
www.theranosticshealth.com
Contact
Categories